Astrotech’s BreathTest-1000 Confirmed to Detect Lung Disease Metabolites at Parts Per Billion
March 27 2020 - 8:00AM
Business Wire
Astrotech Corporation [NASDAQ: ASTC] announced that the
BreathTest-1000™ lung disease screening device that is under
development detects a known metabolite that is associated with lung
diseases at very low parts per billion (ppb) concentrations. On
March 25, the Company announced that it is working on developing
the BreathTest-1000™ to detect volatile organic compound
metabolites present in lung diseases such as the Coronavirus
(“COVID-19”) and pneumonia.
“The Company just reached a milestone in its vision of providing
what it believes to be a highly accurate field instrument that,
subject to applicable regulatory approval, may provide lung disease
testing worldwide. Today’s news is exciting because it accelerates
the development process of the BreathTest-1000™ and we believe gets
us closer to joining the front-line in the fight against lung
diseases, such as COVID-19,” stated Thomas B. Pickens III, Chairman
and Chief Executive Officer of Astrotech Corporation.
“The Company was able to move quickly in the development of the
BreathTest-1000™ because the core mass spectrometry technology it
utilizes has been fully commercialized and deployed for explosives
trace detection. Our goal is to satisfy all regulatory requirements
for the BreathTest-1000™ as rapidly as possible once the necessary
application developments are completed. We believe that few, if
any, changes will need to be made to the underlying technology. We
plan to devote our efforts towards developing a simple and
consistent sample introduction system,” Mr. Pickens concluded.
About Astrotech Corporation
Astrotech (NASDAQ: ASTC) is a science and technology development
and commercialization company that launches, manages, and builds
scalable companies based on innovative technology in order to
maximize shareholder value. 1st Detect develops, manufactures, and
sells explosives trace detectors for use in the security and
detection market. AgLAB develops, manufactures, and sells chemical
analyzers for use in the agriculture market. BreathTech is
developing a breath analysis tool to provide early detection of
lung diseases. Astrotech is headquartered in Austin, Texas. For
information, please visit www.astrotechcorp.com.
This press release contains forward-looking statements that are
made pursuant to the Safe Harbor provisions of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements are subject to risks, trends, and uncertainties that
could cause actual results to be materially different from the
forward-looking statement. These factors include, but are not
limited to, whether we can successfully develop our proprietary
technologies and whether the market will accept our products and
services, as well as other risk factors and business considerations
described in the Company’s Securities and Exchange Commission
filings including the annual report on Form 10-K. Any
forward-looking statements in this document should be evaluated in
light of these important risk factors. The Company assumes no
obligation to update these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200327005114/en/
Eric Stober, Chief Financial Officer, Astrotech Corporation,
(512) 485-9530
Astrotech (NASDAQ:ASTC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astrotech (NASDAQ:ASTC)
Historical Stock Chart
From Apr 2023 to Apr 2024